It is to provide a novel LXRß agonist that is useful as a preventative and/or therapeutic agent for atherosclerosis arteriosclerosis such as those resulting from diabetes dyslipidemia hypercholesterolemia lipid-related diseases inflammatory diseases that are caused by inflammatory cytokines skin diseases such as allergic skin diseases diabetes or Alzheimers disease. It is a carbinol compound represented by the following general formula (I) or salt thereof, or their solvate.